MDT

96.07

-0.39%↓

146.68

-0.14%↓

VEEV

225

-2.38%↓

HQY

84.48

+1.71%↑

PHR.US

16.26

-1.16%↓

MDT

96.07

-0.39%↓

146.68

-0.14%↓

VEEV

225

-2.38%↓

HQY

84.48

+1.71%↑

PHR.US

16.26

-1.16%↓

MDT

96.07

-0.39%↓

146.68

-0.14%↓

VEEV

225

-2.38%↓

HQY

84.48

+1.71%↑

PHR.US

16.26

-1.16%↓

MDT

96.07

-0.39%↓

146.68

-0.14%↓

VEEV

225

-2.38%↓

HQY

84.48

+1.71%↑

PHR.US

16.26

-1.16%↓

MDT

96.07

-0.39%↓

146.68

-0.14%↓

VEEV

225

-2.38%↓

HQY

84.48

+1.71%↑

PHR.US

16.26

-1.16%↓

Home・Aktien・Akebia Therapeutics Inc

Akebia Therapeutics Inc

Open

BrancheGesundheitswesen

1.36 -4.23

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.3599999999999999

Max

1.3599999999999999

Schlüsselkennzahlen
By Trading Economics
Einkommen	293K 540K
Verkäufe	-3.7M 59M
Gewinnspanne	0.919
Angestellte	181
EBITDA	-1.2M 6.2M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+280.54% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-161M 401M
Vorheriger Eröffnungskurs	5.59
Vorheriger Schlusskurs	1.36

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

2.345 / N/A Unterstützung & Widerstand

Akebia Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Jan. 2026, 19:05 UTC

Wichtige Markttreiber

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

13. Jan. 2026, 23:41 UTC

Market Talk

Nikkei May Rise on Japan Election Hopes -- Market Talk

13. Jan. 2026, 23:41 UTC

Market Talk

Global Equities Roundup: Market Talk

13. Jan. 2026, 23:33 UTC

Market Talk

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

13. Jan. 2026, 23:13 UTC

Akquisitionen, Fusionen, Übernahmen

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

13. Jan. 2026, 23:10 UTC

Akquisitionen, Fusionen, Übernahmen

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

13. Jan. 2026, 23:03 UTC

Market Talk

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

13. Jan. 2026, 21:50 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

13. Jan. 2026, 21:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Basic Materials Roundup: Market Talk

13. Jan. 2026, 21:20 UTC

Akquisitionen, Fusionen, Übernahmen

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

13. Jan. 2026, 21:20 UTC

Akquisitionen, Fusionen, Übernahmen

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

13. Jan. 2026, 21:20 UTC

Akquisitionen, Fusionen, Übernahmen

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

13. Jan. 2026, 21:15 UTC

Akquisitionen, Fusionen, Übernahmen

VERSANT Completes Acquisition Of Free TV Networks >VSNT

13. Jan. 2026, 21:08 UTC

Akquisitionen, Fusionen, Übernahmen

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

13. Jan. 2026, 20:39 UTC

Market Talk

Silver Settles at Another New High -- Market Talk

13. Jan. 2026, 20:21 UTC

Market Talk

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

13. Jan. 2026, 20:17 UTC

Market Talk

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

13. Jan. 2026, 19:08 UTC

Akquisitionen, Fusionen, Übernahmen

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

13. Jan. 2026, 19:03 UTC

Ergebnisse

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

13. Jan. 2026, 18:50 UTC

Ergebnisse

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

13. Jan. 2026, 17:54 UTC

Market Talk

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

13. Jan. 2026, 17:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Global Equities Roundup: Market Talk

13. Jan. 2026, 17:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

13. Jan. 2026, 17:49 UTC

Market Talk

Analysts Call For Potential Record Ethanol Output -- Market Talk

13. Jan. 2026, 17:38 UTC

Market Talk

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

13. Jan. 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

13. Jan. 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

13. Jan. 2026, 17:20 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Basic Materials Roundup: Market Talk

13. Jan. 2026, 17:19 UTC

Market Talk

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

13. Jan. 2026, 17:15 UTC

Market Talk

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Peer-Vergleich

Kursveränderung

Akebia Therapeutics Inc Prognose

Kursziel

By TipRanks

280.54% Vorteil

12-Monats-Prognose

Durchschnitt 5.67 USD 280.54%

Hoch 6 USD

Tief 5 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Akebia Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

3 ratings

Buy

Halten

Sell

Basierend auf 3 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Akebia Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

2.345 / N/AUnterstützung & Widerstand

Recent bullish events outweigh bearish events.

All events are bullish.

Finanzen

Über Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.